(Q52839674)

8 May 2018

title

Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection. (English)

1 reference

8 May 2018

main subject

Clostridium difficile

0 references

author

Jane Freeman

5

1 reference

8 May 2018

author name string

C H Chilton

1

1 reference

8 May 2018

G S Crowther

2

1 reference

8 May 2018

S L Todhunter

3

1 reference

8 May 2018

S Nicholson

4

1 reference

8 May 2018

L Chesnel

6

1 reference

8 May 2018

M H Wilcox

7

1 reference

8 May 2018

language of work or name

English

0 references

publication date

9 May 2014

1 reference

8 May 2018

Journal of Antimicrobial Chemotherapy

published in

1 reference

8 May 2018

volume

69

1 reference

8 May 2018

issue

9

1 reference

8 May 2018

page(s)

2426-2433

1 reference

8 May 2018

Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU141

Economic healthcare costs of Clostridium difficile infection: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU141

Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU141

Emergence of reduced susceptibility to metronidazole in Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU141

Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU141

Validation of a Three-Stage Compound Continuous Culture System for Investigating the Effect of Retention Time on the Ecology and Metabolism of Bacteria in the Human Colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU141

Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU141

Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU141

Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU141

Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU141

Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU141

Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU141

Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU141

Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU141

Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU141

Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU141

21 January 2018

Identifiers

DOI

10.1093/JAC/DKU141

1 reference

8 May 2018

1 reference

8 May 2018